Prospective Grant of Start-up Exclusive Evaluation Option Patent License: “The Development and Use of Diazeniumdiolated and Hybrid Diazeniumdiolated Compounds for the Treatment of Ovarian Cancer in Humans”, 16406 [2017-06545]
Download as PDF
16406
Federal Register / Vol. 82, No. 63 / Tuesday, April 4, 2017 / Notices
of the contemplated Exclusive Patent
License. Comments and objections to
this notice submitted will not be made
available for public inspection and, to
the extent permitted by law, will not be
released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: March 21, 2017.
Cristina Thalhammer-Reyero,
Senior Licensing and Patenting Manager,
Office of Technology Transfer and
Development, National Heart, Lung, and
Blood Institute.
[FR Doc. 2017–06546 Filed 4–3–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Start-up
Exclusive Evaluation Option Patent
License: ‘‘The Development and Use of
Diazeniumdiolated and Hybrid
Diazeniumdiolated Compounds for the
Treatment of Ovarian Cancer in
Humans’’
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of a Start-up Exclusive Evaluation
Option License to practice the
inventions embodied in the Patents and
Patent Applications listed in the
Supplementary Information section of
this notice to Tar Meta Biosciences, Inc.
(‘‘TarMeta’’) located in King of Prussia,
PA, USA.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before April 19, 2017 will be
considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
Start-up Exclusive Evaluation Option
License should be directed to: Kathleen
Higinbotham, Senior Technology
Transfer Manager, NCI Technology
Transfer Center, Riverside 5, Suite 400,
8490 Progress Dr., Frederick, MD 21701,
Telephone: (301)-624–8775; Facsimile:
(301)-631–3027 Email: higinbok@
mail.nih.gov.
SUPPLEMENTARY INFORMATION:
asabaliauskas on DSK3SPTVN1PROD with NOTICES
SUMMARY:
Intellectual Property
(1) E–025–2010/0 entitled ‘‘Nitric Oxidebased Cancer Therapeutic Agents For Lung
VerDate Sep<11>2014
16:21 Apr 03, 2017
Jkt 241001
Cancers With Elevated Levels Of Reactive
Oxygen Species (ROS) And/or Low Levels Of
Antioxidant Defense/DNA Repair
Mechanisms.’’
(a) United States Provisional Patent
Application No. 61/261,175 filed November
13, 2009;
(b) PCT Application No. PCT/US2010/
056446 filed November 12, 2010;
(c) United States Patent Application No.
13/509,431 filed June 01, 2012, US Patent
9,205,091 issued December 08, 2015;
(d) Australian Patent Application No.
2010319398 filed May 09, 2012;
(e) Canadian Patent Application No.
2,780,633 filed May 10, 2012;
(f) European Patent Application No.
10778814.3 filed May 14, 2012;
(2) E–220–2011/0 entitled ‘‘Hybrid
Diazeniumdiolated Compounds,
Pharmaceutical Compositions, And Method
Of Treating Cancer.’’
(a) United States Provisional Patent
Application No. 61/549,862, filed October 21,
2011;
(b) PCT Application No. PCT/US2012/
060785 filed October 18, 2012;
(c) United States Patent Application No.
14/352,096 filed April 16, 2014, US Patent
9,168,266 issued October 27, 2015;
(d) Australian Patent Application No.
2012326105 filed April 14, 2014;
(e) Canadian Patent Application No.
2,852,682 filed April 14, 2014;
(f) European Patent Application No.
12841601.3 filed April 14, 2014, European
Patent 2768824 issued December 07, 2016;
(i) German Patent 602012026435.7 issued
December 07, 2016;
(ii) French Patent 2768824 issued
December 07, 2016; and
(iii) UK Patent 2768824 issued December
07, 2016.
The patent rights in these inventions
have been assigned to the government of
the United States of America.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to ‘‘The
development and use of
diazeniumdiolated and hybrid
diazeniumdiolated compounds for the
treatment of ovarian cancer in humans.’’
The present inventions describe the
use of diazeniumdiolate-based nitric
oxide (NO)-releasing compounds
wherein the cancer cell has an elevated
level of reactive oxygen species (ROS),
as well as the use of hybrid prodrug
molecules that combine a
diazeniumdiolated compound and a
poly(ADP-ribose) polymerase (PARP)
inhibitor in cancer cells to produce
synergistic effects, whether alone or as
an adjuvant for other therapies. The
hybrid prodrug is expected to enhance
cytotoxicity by creating DNA damage
with NO and preventing its repair with
the PARP inhibitor. The prodrug and
the hybrid are activated by glutathione
S-transferase and are predicted to be
effective in cancers with reactive oxygen
species (ROS), both of which are
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
elevated in many cancers. In addition,
the prodrug and hybrid may have
synergy with therapeutics (such as
proteasome inhibitor bortezomib and
doxorubicin) which act through
generation of ROS. Taken together, these
features suggest that the prodrug and
hybrid may have therapeutic
applications in cancer patients whose
tumors include high levels of ROS.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective Start-up Exclusive
Evaluation Option License will be
royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in
the prospective field of use that are filed
in response to this notice will be treated
as objections to the grant of the
contemplated Start-up Exclusive
Evaluation Option License Agreement.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: March 21, 2017.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2017–06545 Filed 4–3–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
E:\FR\FM\04APN1.SGM
04APN1
Agencies
[Federal Register Volume 82, Number 63 (Tuesday, April 4, 2017)]
[Notices]
[Page 16406]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-06545]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Start-up Exclusive Evaluation Option Patent
License: ``The Development and Use of Diazeniumdiolated and Hybrid
Diazeniumdiolated Compounds for the Treatment of Ovarian Cancer in
Humans''
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Cancer Institute, an institute of the National
Institutes of Health, Department of Health and Human Services, is
contemplating the grant of a Start-up Exclusive Evaluation Option
License to practice the inventions embodied in the Patents and Patent
Applications listed in the Supplementary Information section of this
notice to Tar Meta Biosciences, Inc. (``TarMeta'') located in King of
Prussia, PA, USA.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute's Technology Transfer
Center on or before April 19, 2017 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated Start-up Exclusive Evaluation
Option License should be directed to: Kathleen Higinbotham, Senior
Technology Transfer Manager, NCI Technology Transfer Center, Riverside
5, Suite 400, 8490 Progress Dr., Frederick, MD 21701, Telephone: (301)-
624-8775; Facsimile: (301)-631-3027 Email: higinbok@mail.nih.gov.
SUPPLEMENTARY INFORMATION:
Intellectual Property
(1) E-025-2010/0 entitled ``Nitric Oxide-based Cancer
Therapeutic Agents For Lung Cancers With Elevated Levels Of Reactive
Oxygen Species (ROS) And/or Low Levels Of Antioxidant Defense/DNA
Repair Mechanisms.''
(a) United States Provisional Patent Application No. 61/261,175
filed November 13, 2009;
(b) PCT Application No. PCT/US2010/056446 filed November 12,
2010;
(c) United States Patent Application No. 13/509,431 filed June
01, 2012, US Patent 9,205,091 issued December 08, 2015;
(d) Australian Patent Application No. 2010319398 filed May 09,
2012;
(e) Canadian Patent Application No. 2,780,633 filed May 10,
2012;
(f) European Patent Application No. 10778814.3 filed May 14,
2012;
(2) E-220-2011/0 entitled ``Hybrid Diazeniumdiolated Compounds,
Pharmaceutical Compositions, And Method Of Treating Cancer.''
(a) United States Provisional Patent Application No. 61/549,862,
filed October 21, 2011;
(b) PCT Application No. PCT/US2012/060785 filed October 18,
2012;
(c) United States Patent Application No. 14/352,096 filed April
16, 2014, US Patent 9,168,266 issued October 27, 2015;
(d) Australian Patent Application No. 2012326105 filed April 14,
2014;
(e) Canadian Patent Application No. 2,852,682 filed April 14,
2014;
(f) European Patent Application No. 12841601.3 filed April 14,
2014, European Patent 2768824 issued December 07, 2016;
(i) German Patent 602012026435.7 issued December 07, 2016;
(ii) French Patent 2768824 issued December 07, 2016; and
(iii) UK Patent 2768824 issued December 07, 2016.
The patent rights in these inventions have been assigned to the
government of the United States of America.
The prospective exclusive license territory may be worldwide and
the field of use may be limited to ``The development and use of
diazeniumdiolated and hybrid diazeniumdiolated compounds for the
treatment of ovarian cancer in humans.''
The present inventions describe the use of diazeniumdiolate-based
nitric oxide (NO)-releasing compounds wherein the cancer cell has an
elevated level of reactive oxygen species (ROS), as well as the use of
hybrid prodrug molecules that combine a diazeniumdiolated compound and
a poly(ADP-ribose) polymerase (PARP) inhibitor in cancer cells to
produce synergistic effects, whether alone or as an adjuvant for other
therapies. The hybrid prodrug is expected to enhance cytotoxicity by
creating DNA damage with NO and preventing its repair with the PARP
inhibitor. The prodrug and the hybrid are activated by glutathione S-
transferase and are predicted to be effective in cancers with reactive
oxygen species (ROS), both of which are elevated in many cancers. In
addition, the prodrug and hybrid may have synergy with therapeutics
(such as proteasome inhibitor bortezomib and doxorubicin) which act
through generation of ROS. Taken together, these features suggest that
the prodrug and hybrid may have therapeutic applications in cancer
patients whose tumors include high levels of ROS.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective Start-up Exclusive Evaluation Option License
will be royalty bearing, and the prospective exclusive license may be
granted unless within fifteen (15) days from the date of this published
notice, the National Cancer Institute receives written evidence and
argument that establishes that the grant of the license would not be
consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in the prospective field of use
that are filed in response to this notice will be treated as objections
to the grant of the contemplated Start-up Exclusive Evaluation Option
License Agreement. Comments and objections submitted to this notice
will not be made available for public inspection and, to the extent
permitted by law, will not be released under the Freedom of Information
Act, 5 U.S.C. 552.
Dated: March 21, 2017.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2017-06545 Filed 4-3-17; 8:45 am]
BILLING CODE 4140-01-P